Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase IV
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 27 Jul 2017 Status changed from active, no longer recruiting to completed.
- 26 Sep 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.